Artal Group S.A. Rubius Therapeutics, Inc. Transaction History

Artal Group S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $763,100 - $2.14 Million	-1,658,914 Reduced 44.82%	2,042,666 $886,000
Q4 2021 Feb 11, 2022	SELL	$9.68 - $17.74 $4.4 Million - $8.05 Million	-454,045 Reduced 10.93%	3,701,580 $35.8 Million
Q3 2021 Nov 12, 2021	SELL	$17.6 - $25.91 $8.42 Million - $12.4 Million	-478,166 Reduced 10.32%	4,155,625 $74.3 Million
Q2 2021 Aug 13, 2021	SELL	$22.26 - $28.43 $5.57 Million - $7.11 Million	-250,000 Reduced 5.12%	4,633,791 $113 Million
Q1 2021 May 14, 2021	BUY	$8.02 - $32.01 $8.86 Million - $35.4 Million	1,104,878 Added 29.24%	4,883,791 $129 Million
Q3 2020 Nov 13, 2020	SELL	$4.65 - $6.25 $341,440 - $458,925	-73,428 Reduced 1.91%	3,778,913 $18.9 Million
Q2 2020 Aug 14, 2020	SELL	$4.01 - $6.88 $126,114 - $216,376	-31,450 Reduced 0.81%	3,852,341 $23 Million
Q1 2020 May 14, 2020	BUY	$3.74 - $9.84 $3.93 Million - $10.3 Million	1,050,000 Added 37.05%	3,883,791 $17.3 Million
Q2 2019 Aug 09, 2019	SELL	$13.5 - $19.94 $1.01 Million - $1.5 Million	-75,000 Reduced 2.58%	2,833,791 $44.6 Million
Q3 2018 Nov 09, 2018	BUY	$20.06 - $26.94 $58.4 Million - $78.4 Million	2,908,791 New	2,908,791 $69.8 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.